Non‐steroidal anti‐inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case–control analysis within a series of patients undergoing cholecystectomy
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35238 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Lorena Rosa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Gallbladder Neoplasms, Inflammation, Precancerous Conditions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias, NIH HHS, US National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.
Abstract (Originalsprache)
Inflammation has been associated with the development of gallbladder cancer (GBC). However, little is known about the associations of both, inflammation and the use of non‐steroidal anti‐inflammatory drugs (NSAIDs), with preneoplastic lesions. We analyzed the association of NSAIDs and gallbladder dysplasia in 82 patients with dysplasia and 1843 patients with gallstones among symptomatic patients from a high‐risk population. We also analyzed associations for 33 circulating immune‐related proteins in a subsample of all 68 dysplasia cases diagnosed at the time of sample selection and 136 gallstone controls. We calculated age‐ and sex‐adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). Biliary colic was reported among most cases (97.6%) and controls (83.9%). NSAID use was inversely associated with gallbladder dysplasia (OR: 0.48, 95%CI: 0.26–0.83). Comparing the highest versus lowest category of each immune‐related protein, eight proteins were inversely associated with dysplasia with sex‐ and age‐adjusted ORs ranging from 0.30 (95%CI: 0.12–0.77) for IL‐33 to 0.76 (95%CI: 0.59–0.99) for MIP‐1B. Of those, GRO remained associated with dysplasia (OR: 0.64, 95%CI: 0.45–0.91) and BCA‐1 was borderline associated (OR: 0.74, 95%CI: 0.54–1.01) after adjusting the logistic regression model for sex, age, and NSAIDs. In conclusion, NSAID users were less likely to have gallbladder dysplasia, suggesting that NSAIDs might be beneficial for symptomatic gallstones patients. The inverse association between immune‐related markers and dysplasia requires additional research, ideally in prospective studies with asymptomatic participants, to understand the role of the inflammatory response in the natural history of GBC and to address the biological effect of NSAIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Advanced Center for Chronic Diseases, Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago, Chile.
- Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
- Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- Department of Pathology, Dokuz Eylul University, Izmir, Turkey.
ORCID-Profile: Lorena Rosa, Ruth M Pfeiffer, Allan Hildesheim, Jill Koshiol
Förderung
- Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias
- NIH HHS
- US National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics
- Fondo Nacional de Desarrollo Científico y Tecnológico
- National Institutes of Health
Zitieren
APA
Rosa, L., Cook, P., Pfeiffer, R. M., Kemp, T. J., Hildesheim, A., Pehlivanoglu, B., Adsay, V., Bellolio, E., Araya, J. C., Pinto, L., Ferreccio, C., Aguayo, G., Viñuela, E., & Koshiol, J. (2025). Non‐steroidal anti‐inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case–control analysis within a series of patients undergoing cholecystectomy. International Journal of Cancer. https://doi.org/10.1002/ijc.35238
Vancouver
Rosa L, Cook P, Pfeiffer RM, Kemp TJ, Hildesheim A, Pehlivanoglu B, et al. Non‐steroidal anti‐inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case–control analysis within a series of patients undergoing cholecystectomy. International Journal of Cancer. 2025. doi:10.1002/ijc.35238
BibTeX
@article{Rosa2025,
author = {Rosa, Lorena and Cook, Paz and Pfeiffer, Ruth M and Kemp, Troy J and Hildesheim, Allan and Pehlivanoglu, Burcin and Adsay, Volkan and Bellolio, Enrique and Araya, Juan Carlos and Pinto, Ligia and Ferreccio, Catterina and Aguayo, Gloria and Viñuela, Eduardo and Koshiol, Jill},
title = {Non‐steroidal anti‐inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case–control analysis within a series of patients undergoing cholecystectomy},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35238}
}
EUVIMED